USP’s Draft Revisions To Medicare Formulary Guidelines Coming In September
Executive Summary
In addition to their use as a reference for Medicare Part D plans, the current guidelines serve as a benchmark for evaluating the formularies of private insurance plans offered through state exchanges.
You may also be interested in...
USP Formulary Guidelines Back In Spotlight With Essential Health Benefits Proposal
HHS proposes to use USP’s drug classification system, created as a guideline for Medicare Part D formularies, to facilitate “review, analysis and comparison” of the breadth of drug coverage offered by individual and small group private insurance plans beginning in 2014.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.